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Lithium-induced nephropathy: Rate of progression and prog-
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Background. Long-term lithium administration in humans
may lead to chronic tubulointerstitial nephritis, which develops
very slowly. Its progression to end-stage renal disease (ESRD)
has been rarely reported. The aim of this study is to document
the rate of progression of lithium-induced nephropathy and its
prognostic factors, and to provide an estimation of the percent-
age of lithium-induced ESRD in France.
Methods. Two groups have been studied: 54 patients with
lithium-induced renal failure, nine of whom underwent renal
biopsy; and 20 patients who were referred for systematic renal
biopsy, 14 of whom were subsequently followed up. In addition,
a survey of lithium-induced ESRD was conducted in French
dialysis centers.
Results. The mean annual loss of creatinine clearance in
patients with lithium-induced nephropathy was 2.29 mL/min.
Among 74 patients, 12 reached ESRD at a mean age of 65
years. Creatinine clearance at referral and at last follow-up
was inversely related to the duration of lithium therapy in both
univariate and multivariate analyses adjusting for age, gender,
hypertension, and proteinuria. The degree of interstitial fibrosis
on renal biopsy was also related to the lithium duration and
cumulative dose. It was predictive of the final creatinine clear-
ance. About 35% of the patients tested had moderate hypercal-
cemia, due to hyperparathyroidism. The prevalence of lithium-
related ESRD in France was estimated as two per 1000 dialysis
patients. The average latency between onset of lithium therapy
and ESRD was 20 years.
Conclusion. Lithium-induced chronic renal disease is slowly
progressive. Its rate of progression is related to the duration
of lithium administration. Lithium-related ESRD represents
0.22% of all causes of ESRD in France. Regular monitoring
of estimated creatinine clearance is mandatory in long-term
lithium-treated patients.
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Chronic administration of lithium salts has been used
from 1949 for the prophylaxis of recurrences in uni- or
bipolar affective disorders (see review in [1]). Its efficacy
was quickly recognized and it has been widely used by
psychiatrists since the early seventies. In the middle 1970s,
it was estimated that about one in 1000 individuals in
Western countries received lithium therapy [2].
Lithium nephrotoxicity was first documented at the
end of the nineteenth century but this problem was more
extensively investigated in recent decades with the more
widespread use of this drug. Impaired renal concentrat-
ing ability is found in approximately 50% of the patients,
and polyuria and polydipsia (due to nephrogenic diabe-
tes insipidus) occur in about 20% of the patients chroni-
cally treated with lithium [3]. Of interest, this side effect
may persist despite cessation of the treatment, pointing
to irreversible renal damage [4]. The possible develop-
ment of lithium-induced chronic tubulointerstitial ne-
phritis was first demonstrated in 1977 by Hestbech et al
[5] in 14 patients treated with lithium for about 2 to 15
years, five of whom had acute lithium intoxication [5].
Subsequently renal damage induced by long-term lith-
ium treatment in susceptible patients was documented
[6, 7]. Markowitz et al [8] recently reemphasized the
risk of often irreversible biopsy-proven lithium toxicity,
responsible for combined glomerular and tubulointersti-
tial damage.
The question of lithium-induced chronic renal failure
(CRF) has long been debated from the conflicting results
of cross-sectional and longitudinal epidemiologic studies
(see review in [9]). Some of these studies have stressed
how renal insufficiency was infrequent and mild in lith-
ium-treated patients. Others have underlined the effects
of confounding factors on renal function, such as aging,
concomitant and chronic administration of other psy-
chotropic or nonpsychotropic medications, and perhaps
the psychiatric disease itself [2]. From the data collected
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in 14 studies, including 1172 patients, Boton, Gaviria and
Batlle [3] estimated that the prevalence of reduced glo-
merular filtration rate (GFR), measured by different
methods, was 15%.
The aim of the present study is to analyze the rate of
progression of renal failure in a group of patients with
lithium-associated chronic nephritis and to correlate the
progression rate with the duration of lithium therapy and
with the severity of the renal histopathologic changes.
In addition, preliminary epidemiologic data on lithium-
induced end-stage renal disease (ESRD) have been col-
lected to draw attention to this emerging cause of ESRD,
which may increase progressively with time, paralleling
the increasing duration of lithium administration.
METHODS
Patients
Seventy-four patients on lithium therapy were in-
cluded in this study from 1970 to 2001. Fifty-four of them
were referred for CRF to two Paris hospitals (Hoˆpital
Necker and Hoˆpital Bichat-Claude Bernard). Chronic
lithium administration was the only cause of renal dis-
ease. During the same period, six patients on chronic
lithium therapy were seen but excluded from this study
because they had evidence of another cause of renal
disease: bilateral partial nephrectomy for cancer (one
patient), idiopathic retroperitoneal fibrosis (one patient),
ureterohydronephrosis (two patients), reflux nephropa-
thy (one patient), and vasculitis (one patient). The other
20 patients participated, after informed consent, in a
systematic evaluation of lithium nephrotoxicity. These
patients were followed up at Hoˆpital Ste Anne, treated
with lithium for at least 5 years, and then referred to
Necker hospital in 1980 for renal biopsy. Fourteen of
these 20 patients had subsequent follow-up and their
renal status was reevaluated at last examination. Six have
been lost to renal follow-up.
For each serum creatinine measurement, creatinine
clearance was estimated according to the Cockcroft and
Gault formula [10]. For each patient and each period,
with or without lithium, a regression curve was deter-
mined and used to calculate creatinine clearance varia-
tion in mL/min/year.
Data on proteinuria, leucocyturia, hematuria, lithium
dosage, and serum calcium concentration were collected.
Proteinuria was considered as significant when above 300
mg/24 hours. Microhematuria was defined as 10,000
erythrocytes/mL of urine. Patients were considered as
hypertensive when blood pressure was 140/90 mm Hg
or when they were receiving antihypertensive therapy.
The therapeutic range of serum lithium concentration
was 0.5 to 0.8 mmol/L. Acute lithium intoxication was
defined as serum lithium concentration above 1.5 mmol/L
with central nervous system abnormalities, acute renal
failure, and electrocardiographic changes. Hypercalce-
mia was defined as a serum calcium concentration above
2.6 mmol/L. Polyuria was defined as more than 3 L per
24 hours.
Finally, a survey was performed among the French
dialysis centers. Questionnaires were sent to all nephrol-
ogists in charge of the 242 dialysis centers in France to
obtain information on the dialysis patients with lithium-
induced nephropathy. No national registry is available
in France.
Renal pathology
Twenty-nine patients underwent a renal biopsy, 20
belonging to the cohort studied in 1980, and nine to the
group of patients referred for CRF. Renal biopsies were
studied by light microscopy with standard methods. Par-
affin sections were stained with silver (Jones method),
periodic acid-Schiff, hematoxylin and eosin, Masson’s
trichrome, and were examined by the same pathologist
(L.H.N.). The following items were graded according to
a scale of 0 (absent) to 3 (severe): interstitial fibrosis and
tubular atrophy, interstitial inflammation, arteriosclero-
sis and arteriolosclerosis. Interstitial fibrosis was graded
semiquantitatively according to the criteria of Banff clas-
sification used for kidney transplants [11]. The percent-
age of sclerotic glomeruli was recorded. Tubular cysts
and dilatations were defined as tubules with a diameter
of at least 5 times and 2 to 4 times that of normal tubules,
respectively.
Statistical analysis
Continuous variables are reported as mean  SD.
We analyzed the relation between daily lithium dose,
duration of treatment, serum lithium concentration and
three outcome variables: baseline creatinine clearance,
creatinine clearance at the end of follow-up, and decline
in creatinine clearance. The decline in creatinine clear-
ance was also studied continuously in two categories
(below or above 2 mL/min/year), whereas the two other
outcome variables were studied continuously. Chi-square
test, analysis of variance and correlation coefficient were
used to study crude relations between lithium exposure
and the outcome variables. Multiple regression analysis
and logistic regression were used to adjust for (1) age and
gender; (2) age, gender, and hypertension; and (3) age,
gender, and proteinuria. Subsidiary analysis of the rela-
tions between exposure variables and both calcemia and
fibrosis was performed, but these relations were not ad-
justed because of the small number of subjects.
RESULTS
Patients’ characteristics
They are described in Table 1. The female/male gender
ratio is 1.55. The patients have been treated with lithium
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Table 1. Main clinical characteristics of the lithium-treated patients
Patients who
All patients progressed to ESRD Other patients P value
(1) (2) (3) (2) vs. (3)
Number of patients 74 12 62
Gender F/M 46/28 6/6 40/22 NSa
Age at the onset of lithium year 42.910.5 39.912.8 43.59.9 NS
Duration of the lithium therapy year 19.88 21.76.2 19.48.3 NS
Total dose g 52312554 50412762 52602524 NS
Serum lithium concentration mmol/L
Mean 0.620.05 0.620.08 0.670.11 NS
Maximal 0.910.28 0.910.28 1.020.49 NS
Creatinine clearance at the beginning of follow-up
mL/min 62.629.5 39.123.3 67.128.6 0.002
Last creatinine clearance mL/min 41.427 7.22.1 48.124.4 0.0001
Loss of creatinine clearance mL/min/year 2.292.64 4.12.2 1.924.02 NS
Number of hypertensive patients 38 8 30 NSa
Follow-up years 107.8 8.95.5 10.28.1 NS
Number of patients who interrupted lithium therapy
Temporarily 8 3 5 NSa
Definitively 17 3 14
Mean  SD; Student t test.
aChi-square test
since a mean age of 42.9 years, for unipolar (14 patients),
bipolar (57 patients), and schizophrenic-affective disor-
ders (3 patients). The estimated cumulative dose of lith-
ium salt (mostly lithium carbonate) could be calculated
from the medical records of only 66 patients. Fourteen
patients were treated with lithium only, 60 had additional
psychotropic drugs (antidepressants, neuroleptics, or
benzodiazepines). Hypertension was present in 38 pa-
tients whereas only 25 received antihypertensive ther-
apy, including an angiotensin-converting enzyme (ACE)
inhibitor in three patients and an angiotensin II type 1
(AT-1) receptor blocker in three others. The mean num-
ber of medications was 1.65. Nine patients were given
thyroid substitution because of hypothyroidism. Two pa-
tients had regularly taken nonsteroidal anti-inflamma-
tory drugs or analgesics that did not contain phenacetin,
respectively.
Lithium therapy
Mean lithium therapy duration was 19.8 years corre-
sponding to an estimated cumulative lithium salt of 5231
g per patient (Table 1). At least one serum lithium con-
centration was known in 54 patients. The frequency of
lithium measurements was once a month in 21 patients
and about three to four determinations per year in the
others. Mean serum lithium concentration was 0.62
mmol/L. Twenty-one patients had a serum lithium con-
centration above 1 mmol/L at least once. Four patients
had acute lithium intoxication. In two patients this oc-
curred in the first months after dialysis initiation.
Renal abnormalities
Polyuria and polydipsia were present in 25 patients
among 54 (46%). Sixty two patients were examined for
proteinuria and only 11 showed significant proteinuria
(mean, 1.29 g/24 hours; range, 0.35 to 4.1). Six patients
had proteinuria above 1 g/24 hours. Five of these protein-
uric patients had a renal biopsy. Thirteen patients out
of 55 (24%) had microscopic hematuria, 10 of these
patients had a renal biopsy, and 16 out of 52 (31%) had
leucocyturia. At the beginning of the follow-up, mean
creatinine clearance was 62.6 mL/min and dropped to
41.4 mL/min at the end of the follow-up, after a mean
period of 10  7.8 years (range, 3 months to 32 years).
Renal function loss, estimated in 70 patients followed
up for more than 1 year and calculated from creatinine
clearance, was 2.29  2.64 mL/min/year (Table 1 and
Fig. 1). Two patients who had lithium therapy in two
different periods of their lives are reported twice in this
figure.
Twelve patients reached ESRD at a mean age of 65
years (range, 46 to 85 years). They had begun the treat-
ment at the same age as the other patients, had taken
the same amount of lithium over a slightly longer period
of time (Table 1). In five of these 12 patients, multiple
serum lithium concentrations were available and did not
differ from those of the other patients. At entry in the
study, these patients had a more impaired renal function
than the others and their mean annual loss of creatinine
clearance was slightly higher (P  0.08). Among the
nine patients who progressed to ESRD and in whom
proteinuria was looked for, six had a significant protein-
uria, whereas among the other 52 patients, only four had
proteinuria (P  0.0001).
Relation between lithium therapy and renal
functional impairment
Patients who received lithium for 20 years or more
had lower creatinine clearance at entry into the study
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Fig. 1. Evolution of estimated creatinine clear-
ance over time in 35 patients on lithium ther-
apy. Each line denotes the evolution in one
patient followed up for more than 1 year.
Table 2. Relations between lithium daily dose, treatment duration, and progression of renal function
Creatinine clearance Decline of creatinine clearance
At entry into the study At the end of follow-up Mean annual decline Decline 2 mL/min/year
Lithium salt
administration N Mean  SD N Mean  SD N Mean  SD % ORa (95% CI)
Daily dose
750 mg 25 4618 24 3417 24 1.655.50 25.0 1
750 mg 41 7331 41 4830 39 2.512.70 51.3 3.0 (1.0–9.3)
Pb 0.001 0.06 0.45
Duration
20 years 29 7236 29 5334 27 2.535.71 44.4 1
20 years 43 5622 42 3217 42 2.071.96 45.2 0.9 (0.3–2.6)
Pb 0.020 0.001 0.59
a Odds ratios adjusted for age and gender (95% confidence interval)
b P value of the comparison between groups from the multiple regression analysis, including age and gender as covariates
and at the end of follow-up than the others (Table 2).
The patients who received a daily dose above 750 mg/
day had a slightly but not significantly greater annual loss
of creatinine clearance. However, patients who received
more than 750 mg/day were three times more likely to
experience an annual creatinine clearance decline above
2 mL/min than those who recieved a lower dose. These
relations were not explained by age and gender (Table
2) and remained unchanged after adjusting for either
hypertension or proteinuria (data not shown).
Estimated creatinine clearance inversely correlated
with the length of lithium therapy (Fig. 2) and more weakly
with the mean serum lithium concentration. However,
it did not correlate with maximal serum lithium concen-
tration or lithium daily dose. This is probably explained
by reverse causation (i.e., the progressive decrease in
lithium dose as far as renal function declined).
The treatment was stopped in 25 patients, temporarily
in eight (lithium had to be reintroduced to control the
psychiatric disease) and definitively in 17 other patients.
Eleven patients were followed up for more than 1 year
before and after their treatment interruption. There was
a slight reduction in the rate of progression of CRF
after the lithium treatment interruption (P  0.067). Of
interest, six of the 12 dialysis patients had interruption
of lithium therapy. Despite definitive discontinuation,
three patients progressed to ESRD in 2 to 13 years. Their
estimated creatinine clearance at interruption ranged
from 15 to 27 mL/min. Lithium therapy had to be reintro-
duced during regular dialysis period in two patients.
When creatinine clearance was above 40 mL/min at lith-
ium discontinuation, renal function improved in five of
seven patients with a mean increase in creatinine clear-
ance of 1.57 mL/min/year; whereas it continued to deteri-
orate in 12 of 18 patients at a mean rate of 2.64 mL/
min/year when creatinine clearance was 40 mL/min at
cessation. Furthermore, when lithium was interrupted
below 25 mL/min all patients continued to deteriorate.
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Fig. 2. Correlation between creatinine clearance at the end of follow-
up and lithium treatment duration. () Each patient.
Calcium disorders
A concentration of serum calcium was determined in
46 patients. Its mean was 2.52  0.23 mmol/L. Sixteen
patients (35.6%) had hypercalcemia ranging from 2.60
to 3.0. Parathyroid hormone (PTH) level was measured
in only nine hypercalcemic patients. The mean PTH level
was 96.4 pg/mL (range, 48 to 180; normal, 10 to 65). Six
patients had morphologic investigation of parathyroid
glands by ultrasonography and/or 99m-technetium (99mTc)
sesta-MIBI scintigraphy. It was normal in one patient,
whereas the others had a parathyroid adenoma, which
was operated successfully in three patients. Surgery
showed parathyroid adenoma superimposed on hyper-
plasia in one case. Nephrocalcinosis was demonstrated
by ultrasonography in a hypercalcemic patient.
Renal biopsy
Interstitial fibrosis and tubular atrophy were the most
predominant lesions, observed in 24 patients (85%).
Moderate arteriosclerosis was present in 24 patients
(85%). Fourteen of these had hypertension. Only three
patients had severe arteriolosclerosis. The percentage of
sclerotic glomeruli ranged from 0% to 90% (median
10%). Only one patient had a lesion of focal segmental
glomerulosclerosis (FSGS). Tubular cysts were found in
eight patients (28%) and tubular dilatations in 19 pa-
tients (66%).
Statistical analysis showed that the degree of intersti-
tial fibrosis did not correlate with the age at renal biopsy
(data not shown). On the contrary, the degree of intersti-
tial fibrosis was related to the duration of lithium admin-
istration (Table 3) and to the cumulative dose of lithium
(P  0.045) (Student t test). Interstitial fibrosis was sig-
nificantly more severe in patients with the lower creati-
nine clearance at renal biopsy and at the end of follow-
up (Table 3). Tubular dilatations and cysts were more
Table 3. Creatinine clearance and lithium therapy duration
according to the degree of interstitial fibrosis on renal biopsy
Lithium
Creatinine Creatinine duration
Interstitial clearance at clearance at at renal
fibrosis renal biopsy last follow-up biopsy
grading mL/min mL/min year
0 and 1 81.423.8 70.930.7 6.22.9
2 and 3 54.923.0 36.726.4 10.45.7
P value 0.005 0.003 0.02
MeanSD; Student t test.
frequent in patients with the longer duration of lithium
therapy (P  0.027) whereas these two abnormalities
were not predictive of renal function impairment and
progression (not shown).
Prospective study
The 14 patients of the Ste. Anne cohort underwent
renal biopsy at a mean age of 54.8 years, after a 5 to 8
year lithium administration (cumulative dose 2052.5 g).
None had proteinuria. As expected, renal histopatho-
logic changes were mild to moderate. Interstitial fibrosis
was graded as two in eight, one in four, and zero in two
patients. Mean creatinine clearance was 77.8 mL/min at
lithium initiation, 65.2 at renal biopsy, and 40.8 at last
follow-up. Mean annual loss of creatinine clearance was
1.93 mL/min. These patients were prospectively fol-
lowed up during a 18.9-year period. The total mean dura-
tion of lithium therapy was 22.8 years, corresponding to
a mean total dose of lithium salt of 6905 g. Two patients
developed mild hypercalcemia. It is difficult to draw firm
conclusions from such a small group of patients. Of inter-
est, however, the final creatinine clearance was 61.3 mL/
min in the two patients with grade 0 fibrosis versus 36.0
mL/min in the eight patients with grade 2 fibrosis on
renal biopsy, and the only patient who progressed to
ESRD had grade 2 interstitial fibrosis on the renal biopsy
performed 18 years earlier.
Survey analysis
The questionnaire was answered by 130 dialysis cen-
ters. The response rate to the survey was therefore 56%.
Among the 10,726 dialysis patients treated in these cen-
ters (representing approximately 40% of all dialysis pa-
tients in France), 24 had lithium-induced nephropathy
(i.e., a prevalence of 0.22% dialysis patients).
At the Necker Hospital between 1989 and 2000, dial-
ysis therapy was initiated in 1391 patients. Two had lith-
ium-induced nephropathy, a percentage of 0.14% among
incident dialysis patients.
Figure 3 shows the age distribution of the 24 dialysis
patients at the beginning of lithium therapy and at the
dialysis initiation, respectively. This figure underlines the
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Fig. 3. Survey analysis in 130 French dialysis centers. Age distribution
of the patients who progressed to end-stage renal disease (ESRD), at
the beginning of lithium therapy ( ) and at initiation of dialysis ().
latency (approximately 20 years) between the onset of
the treatment and the need for dialysis therapy.
DISCUSSION
Although the link between lithium and CRF has been
disputed in the past [1, 7], it is unequivocally established
that long-term lithium administration may induce chronic
tubulointerstitial nephropathy leading to renal failure
[5, 8]. The present series includes 74 patients treated
with lithium for a mean period of about 20 years. Other
causes of renal disease were excluded. Creatinine clear-
ance was inversely correlated with the duration of lith-
ium therapy. Similarly, in those patients who underwent
renal biopsy, the degree of interstitial fibrosis was related
to the duration of lithium administration and with the
cumulative dose of lithium salt. Lithium nephrotoxicity
may develop chronically in the absence of episodes of
lithium intoxication. Less than 50% of the patients had
serum lithium concentration above 1 mmol/L at one dos-
age or more. These results strongly suggest that the dura-
tion of lithium therapy and the cumulative dose of lith-
ium are the major determinants of nephrotoxicity.
Lithium-induced nephropathy develops slowly over
several decades. This is well demonstrated in the two
multicenter studies performed by the same group in Swe-
den 12 years apart. Only 4% of the patients receiving
lithium for a mean duration of 6.5 years had elevated
serum creatinine levels, whereas this was found in 12%
of the patients after 19 years of administration [12, 13].
In our study, we have been able to estimate the mean
annual loss of creatinine clearance in 70 lithium-treated
patients, 2.29 mL/min. Unsurprisingly, it is slow as in
most chronic renal tubulointerstitial disorders. Of inter-
est, it is close to the decline in GFR recently measured
in the African American Study of Kidney Disease and
Hypertension, namely 2.07 and 3.22 mL/min per 1.73 m2
per year in the ramipril and amlodipine groups, respec-
tively [14].
Lithium-induced renal failure may progress to ESRD.
A long period of time is needed to reach this stage. This
explains why only anecdotal cases were reported in the
past [15, 16]. However, in the study by Markowitz et al
[8], eight of 24 patients who underwent renal biopsy
progressed to ESRD. Of all the patients who underwent
renal biopsy in our study, only one reached ESRD. Renal
biopsies were performed earlier and the lesions were
less severe than in the study by Markowitz et al (e.g.,
global sclerosis is affecting 20% versus 57.5% of the
glomeruli). In our study, regular dialysis became neces-
sary in 12 of 74 patients, at a mean age of 65 years. The
estimated cumulative dose of lithium was similar to that
of other patients, suggesting that factors other than lith-
ium contributed to progression. These patients had more
impaired renal function at entry in the study. Of note,
proteinuria was more common in patients who devel-
oped ESRD, supporting the suggestion made by Mar-
kowitz et al [8] that FSGS is not unusual and contributes
to progression in these cases. However FSGS was very
rarely found in our patients.
From the survey performed in France, the percentage
of lithium-induced ESRD among dialysis patients may
be estimated as three per 1000. This value should be
considered as a rough and approximate estimation. In-
deed, there is no national registry of dialysis patients in
France. To our knowledge, lithium-induced nephropathy
is identified in only one registry, ANZDATA. In 2000,
the incidence rate was 0.7% in Australia (12 cases among
1723 new patients) and 0.2% in New Zealand (1 of 411
new patients), which is slightly higher than in our estima-
tion [17]. In our survey, we have possibly selected centers
with well-known patients with lithium-induced nephrop-
athy. Conversely, it is possible that if nephrologists have
not paid enough attention to this type of kidney disease,
then the reporting could have been underestimated.
It may be expected that interruption of lithium therapy
in patients with renal disease has some beneficial effects
but also some potential detrimental psychiatric conse-
quences. In patients with established renal disease, it is
difficult to demonstrate the beneficial renal effects of
interrupting lithium [4]. In 11 patients followed up for
more than 1 year before and after interruption, the rate
of renal progression was slightly but not significantly less
rapid after lithium cessation. In contrast, three patients
progressed to ESRD despite interruption. Improvement
in GFR has been reported by Aurell and Hestbech [18]
after lithium discontinuation in a patient with advanced
renal failure but correction of dehydration may have
contributed to this improvement. In another study [8],
lithium therapy was interrupted in 19 patients with renal
disease. Among the nine whose serum creatinine levels
were above 220 mol/L, seven went on to require dial-
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ysis, whereas in the 10 others whose serum creatinine
levels were below 220 mol/L, only one progressed to
ESRD. Similarly in our study, the probability of renal
improvement is higher when estimated creatinine clear-
ance is above 40 mL/min at lithium discontinuation than
when it is lower. There is probably a point of no return,
where renal fibrosis continues to progress despite sup-
pression of the triggering toxic insult. The psychiatric
risk also has to be taken into account despite the avail-
ability of other mood stabilizers. Lithium is the first line
treatment for the prophylaxis of recurrences in bipolar
affective disorder [19]. It is the only compound that has
clearly demonstrated antisuicide effects in the mainte-
nance treatment of major affective disorders [20]. More-
over, the risk of early recurrence of bipolar illness ap-
pears very high following lithium discontinuation [21].
Besides, some patients, whose illness is well controlled
by lithium therapy, refuse to consider interruption and
substitution. Therefore, the decision to interrupt lithium
and to substitute another drug should involve the patient,
the psychiatrist, and the nephrologist. The results ob-
tained in 14 patients who underwent systematic renal
biopsy in 1980 and were subsequently followed up are
interesting in this regard. The final creatinine clearance
is inversely correlated to the severity of renal interstitial
fibrosis. Renal biopsy findings might be useful to predict
the risk of further progression. Proteinuria is also a
marker of poor prognosis. It deserves symptomatic man-
agement to retard the progression of FSGS. However,
it appears probably late in the course and is not war-
ranted that at this stage, lithium interruption will modify
the course of renal disease.
Lithium-associated hypercalcemia, first reported in
1973 [22], has been subsequently ascribed to hyperpara-
thyroidism (HPT) [23]. Up to 25% of lithium-treated
patients develop hypercalcemia with increased ionized
calcium, independent of plasma volume contraction due
to nephrogenic diabetes insipidus [24]. The study by
Bendz et al [25] has provided evidence for an increased
incidence and prevalence of HPT in patients on very
long-term lithium treatment. The incidence of HPT in
women of 60 years old or older was approximately three
times as high as in women of the general population
[26]. As expected, hypercalcemia is aggravated by the
development of renal failure, which decreases urinary
calcium excretion. In our series, 35% of the patients
tested had moderate hypercalcemia due to HPT. One
patient with chronic hypercalcemia had nephrocal-
cinosis, which may have further impaired renal function.
No intrarenal calcium deposits, however, were found on
renal biopsies. There is a higher proportion (33%) of
parathyroid hyperplasia in lithium-treated patients with
HPT than in HPT patients of the general population,
but parathyroid adenomas still predominate in lithium
patients [25–27]. These parathyroid gland lesions explain
why lithium withdrawal during an average of 8.5 weeks
had no effect on hypercalcemia [25]. The mechanism of
lithium-induced HPT remains ill-defined and may in-
volve direct stimulation of PTH production by lithium
salts [28], a shift to the right in the set point for PTH
secretion [29] and alteration of calcium sensing in para-
thyroid glands.
Lithium-induced nephrogenic diabetes insipidus has
been the subject of many studies. It has been ascribed
to inhibition of magnesium-dependent G proteins that
activate vasopressin-sensitive adenyl cyclase, resulting in
the down-regulation of the vasopressin-regulated water
channel aquaporin-2, routed and expressed at the apical
plasma membrane of principal cells of the collecting duct
[30]. Additional mechanisms have been suggested in lith-
ium-fed rats, increased circulating levels of PTH acting
as partial agonist to arginine vasopressin (AVP) and
thereby inhibiting its hydro-osmotic action [31], and the
down-regulation of urea transporters in the renal inner
medulla [32].
In contrast, the mechanism(s) of tubulointerstitial
changes is (are) still poorly understood. In lithium-fed
animals, tubular lesions, mainly dilatation of tubules,
predominate in distal segments and in collecting ducts.
Glomerulosclerosis tends to be a late feature [33]. In
rats and humans, severe lesions of the mitochondria and
endoplasmic reticulum have been documented [6]. In
vitro, lithium induces inositol depletion [34, 35] and in-
hibits cell cycle progression without affecting cell viabil-
ity, probably via induction of p21Cip [36]. The potential
role of these molecular events in lithium nephrotoxicity
has to be investigated. Some unknown genetic and/or
environmental factors predispose to lithium nephrotox-
icity. Indeed, some patients develop very significant renal
lesions early in the course of lithium treatment, after
4-year [6], 2-year, and 5-year [8] administration. The
proportion of patients who will develop clinically rele-
vant renal toxicity after several decades of lithium ther-
apy, and whether it is restricted to “susceptible” patients,
is still unknown. On the other hand, predisposing factors
may influence the rate of progression of renal disease
and/or renal failure. Epidemiologic studies are required
to evaluate long-term renal consequences of lithium
therapy. Pathophysiologic studies are also needed to
identify these predisposing factors and to understand
how they interact with a nephrotoxic substance.
CONCLUSION
Close monitoring of lithium-treated patients is manda-
tory over the long-term, and close collaboration between
psychiatrists and nephrologists should be encouraged on
this topic. Monitoring should not only include regular
measurements of serum lithium, but also serum creati-
nine and calcium concentrations. The efficacy of lithium
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therapy in the bipolar disorders is so good that some
patients are lost to medical follow-up, regular biochemi-
cal monitoring is omitted, and renal failure is discovered
too late.
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